EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer

Jonas Willmann, Camilla von Wachter, Ronja Zehnder, Edward Christopher Dee, Hanbo Chen, Lizza E L Hendriks, Jordi Remon, Sarah Baker, Michael Mayinger, Nicolaus Andratschke, Narek Shaverdian, Daniel R Gomez und 6 weitere

JAMA Network Open · 29.12.2025 · 8 (12) · e2549685

DOI: 10.1001/jamanetworkopen.2025.49685 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JAMA Network Open, online erschienen am 29.12.2025. Verfasst von Jonas Willmann und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Radiosurgery, Neoplasm Metastasis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Metastasis-directed stereotactic body radiotherapy (SBRT) may be a viable strategy to defer systemic therapy in patients with oligometastatic cancer due to comorbidities, patient preferences, or concerns about adverse effects. To date, the evidence supporting this approach has not been comprehensively assessed.

Objective

To evaluate systemic therapy–free survival (STFS) for different types of oligometastatic cancer after SBRT alone and to quantify adverse events, quality of life, and oncological outcomes. Data Sources A systematic search of PubMed and EMBASE was conducted on July 10, 2024, to identify potentially eligible studies published after 2009. Forward and backward citation tracking was performed to identify additional relevant studies. Study Selection Studies eligible for inclusion in the systematic review were retrospective or prospective with at least 10 patients who received metastasis-directed SBRT and no up-front systemic therapy for oligometastatic cancer (≤5 metastases) irrespective of primary tumor histology. Required outcomes being reported were STFS, progression-free survival, or overall survival. The subgroup of studies reporting STFS at 1 or 2 years were included in a meta-analysis of these pooled outcomes. Data Extraction and Synthesis Two reviewers independently extracted data using predefined forms and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A random-effects model was used for meta-analysis. Main Outcomes and Measures The primary outcome of the meta-analysis was the pooled STFS rate at 1 or 2 years.

Results

Of 29 unique studies (2074 unique patients) included in the systematic review, 13 (984 patients) contributed data to the meta-analysis. The pooled 1- or 2-year STFS rate was 69.7% (95% CI, 57.4%-80.9%) across cancer types. Renal cell cancer demonstrated the highest STFS rate (87.0%; 95% CI, 76.2%-95.2%), followed by prostate cancer (78.1%; 95% CI, 67.4%-87.3%), with lower rates in other cancer types. Among 20 studies reporting adverse events, rates of adverse effects of grade 3 or higher were absent in 15 of 19 studies (79%) and ranged from 2 of 103 (1.9%) to 3 of 34 patients (8.8%) among those that observed severe adverse events. Conclusions and Relevance In this systematic review and meta-analysis, metastasis-directed SBRT alone was associated with meaningful STFS, particularly in patients with oligometastatic prostate or renal cell cancer, with low risks of treatment-related adverse events. These findings suggest that SBRT alone might be an acceptable option instead of immediate systemic therapy in selected patients with oligometastatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryNeoplasm MetastasisHumansMaleQuality of LifeFemaleTreatment Outcome

Autor:innen und Institutionen

  • Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
  • Department of Pulmonary Diseases, GROW-Research Institute for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

Förderung

  • NCI NIH HHS

Zitieren

APA

Willmann, J., von Wachter, C., Zehnder, R., Dee, E. C., Chen, H., Hendriks, L. E. L., Remon, J., Baker, S., Mayinger, M., Andratschke, N., Shaverdian, N., Gomez, D. R., Ricardi, U., Olson, R., Sahgal, A., De Ruysscher, D., Iyengar, P., & Guckenberger, M. (2025). Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer. JAMA Network Open, 8(12), e2549685. https://doi.org/10.1001/jamanetworkopen.2025.49685

Vancouver

Willmann J, von Wachter C, Zehnder R, Dee EC, Chen H, Hendriks LEL, et al. Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer. JAMA Network Open. 2025;8(12):e2549685. doi:10.1001/jamanetworkopen.2025.49685

BibTeX
@article{Willmann2025,
  author = {Willmann, Jonas and von Wachter, Camilla and Zehnder, Ronja and Dee, Edward Christopher and Chen, Hanbo and Hendriks, Lizza E L and Remon, Jordi and Baker, Sarah and Mayinger, Michael and Andratschke, Nicolaus and Shaverdian, Narek and Gomez, Daniel R and Ricardi, Umberto and Olson, Robert and Sahgal, Arjun and De Ruysscher, Dirk and Iyengar, Puneeth and Guckenberger, Matthias},
  title = {Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer},
  journal = {JAMA Network Open},
  year = {2025},
  volume = {8},
  number = {12},
  pages = {e2549685},
  doi = {10.1001/jamanetworkopen.2025.49685}
}
Kostenlos starten →